By Ben Clark, Leif Olson and George Chen ( September 4, 2026, 5:07 PM EDT) -- In a unanimous victory for the generic drug industry, on June 4 the U.S. Supreme Court reversed the U.S. Court of Appeals for the Federal Circuit's decision in Hikma Pharmaceuticals USA Inc. et al. v. Amarin Pharma Inc. and held that Amarin failed to plausibly allege that Hikma induced healthcare providers to infringe Amarin's patents on a cardiovascular medication called Vascepa....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.